With the advent of a possible new blockbuster drug and greater reimbursement levels for the treatment of nicotine, alcohol, and drug addictions, global sales of smoking cessation and addiction treatments are expected to rise from revenues of little over $1.1 billion in 2005 to more than $2.3 billion in 2010, according to Smoking Cessation and Addiction Treatments: A World Market Analysis, a new study released today from Kalorama Information.
Nicotine is clearly the most abused drug worldwide, with over 1.4 billion incidences, including 50 million users in the U.S. alone. Smoking cessation has continually become a particular focus of global health agencies, and the increasing high awareness of effective smoking cessation products have helped to drive market growth.
AdvertisementThe market now dominated by GlaxoSmithKline with its Zyban smoking cessation treatment, and Schering-Plough / Reckitt Benckiser with their Suboxone/Subetex substance abuse treatment, is primed for a dramatic change as Pfizer moves into smoking cessation.
"We believe Pfizer's Chantix will acquire the largest share of the market, overtaking GlaxoSmithKline in smoking cessation, and leading all addiction treatments based on the superior effectiveness of Pfizer's product in clinical studies," notes Melissa Elder, the report's author. "To a more limited extent, new drugs in alcohol and substance abuse treatments will also change those markets."
Smoking Cessation and Addiction Treatments: A World Market Analysis includes world incidence and data for nicotine addiction, drug addiction, and alcohol abuse; current and forecasted revenues through 2010; current and forecasted market share with consideration of new players in the market; reviews of current products and new products in the pipeline; and key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction.
Source: PR Newswire